Vitrakvi Interactions
There are 509 drugs known to interact with Vitrakvi (larotrectinib), along with 1 disease interaction, and 1 alcohol/food interaction. Of the total drug interactions, 67 are major, 423 are moderate, and 19 are minor.
- View all 509 medications that may interact with Vitrakvi
- View Vitrakvi alcohol/food interactions (1)
- View Vitrakvi disease interactions (1)
Most frequently checked interactions
View interaction reports for Vitrakvi (larotrectinib) and the medicines listed below.
- acetaminophen / chlorpheniramine / phenylephrine
- acetazolamide
- Actisite (tetracycline)
- Adriamycin RDF (doxorubicin)
- Advate (antihemophilic factor)
- Adzenys XR-ODT (amphetamine)
- Afinitor Disperz (everolimus)
- Alimta (pemetrexed)
- Alphanate (antihemophilic factor/von willebrand factor)
- aluminum hydroxide / magnesium hydroxide / simethicone
- amlodipine
- amlodipine / hydrochlorothiazide / olmesartan
- anastrozole
- aspirin
- atorvastatin
- Azilect (rasagiline)
- Bactrim DS (sulfamethoxazole / trimethoprim)
- Baraclude (entecavir)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- bimatoprost topical
- bisoprolol
- Botox Cosmetic (onabotulinumtoxinA)
- brimonidine ophthalmic
- budesonide
- calcitonin
- gemfibrozil
- Onpattro (patisiran)
- pyrazinamide
- Sensipar (cinacalcet)
- Xanax (alprazolam)
Vitrakvi alcohol/food interactions
There is 1 alcohol/food interaction with Vitrakvi (larotrectinib).
Vitrakvi disease interactions
There is 1 disease interaction with Vitrakvi (larotrectinib) which include:
Report options
QR code containing a link to this page
More about Vitrakvi (larotrectinib)
- Vitrakvi consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
